Form D · Biotechnology

Direct Biologics, LLC

Austin, TX · CIK 0001953704

Offering snapshot reported Dec 13, 2022 · SEC filing

Reported sold
$11.6M
Indefinite offering
Investors reported
116
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Oct 7, 2022
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Dec 13, 2022Initial$11,569,702No comparison116SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
Yes
Sales commissions
$0
Finders' fees
$0
Form D file number
021-467216
There have been no sales commissions or finders' fees paid to date. The party referenced in Item 12 is entitled to a 5% placement fee for certain placements, subject to the terms of an Engagement Letter, by and between the Issuer and IB Capital LLC.

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
IB Capital LLCNone

Source: Form D, filed Dec 13, 2022. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Mark Adams Executive
Aline M. Betancourt Executive
Gordon Feller Director, Executive
Amy Lightner Executive
Jeffrey Mims Executive
Timothy Moseley Executive
Matthew Rogers Director, Executive
Emil Joseph Schmidt Iv Executive
John Vacalis Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
5301 Southwest Parkway, Suite 415
Austin, TX, 78735